Clinical Trial Update: A Non-interventional Study Evaluating Clinical Utility and Implications on Improved Patient Management of Serum Neurofilament as a Prognostic Marker for Disease Activity in Patients With Relapsing Multiple Sclerosis

View source ↗

Summary

A non-interventional study sponsored by Novartis is evaluating whether serum neurofilament levels can prognosticate disease activity and guide patient managemen…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Multiple Sclerosis | Status: RECRUITING